1. Home
  2. AURA vs CBIO Comparison

AURA vs CBIO Comparison

Compare AURA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

N/A

Current Price

$7.11

Market Cap

631.6M

Sector

Health Care

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$14.20

Market Cap

507.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AURA
CBIO
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
631.6M
507.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
AURA
CBIO
Price
$7.11
$14.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$16.60
★ $31.50
AVG Volume (30 Days)
★ 748.9K
207.6K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $18,500.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$177.36
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.73
$8.72
52 Week High
$9.54
$27.41

Technical Indicators

Market Signals
Indicator
AURA
CBIO
Relative Strength Index (RSI) 57.34 52.66
Support Level $6.65 $10.25
Resistance Level $7.83 $15.11
Average True Range (ATR) 0.41 1.11
MACD 0.11 0.24
Stochastic Oscillator 60.05 56.94

Price Performance

Historical Comparison
AURA
CBIO

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: